Skip to main content
OncoPrescribe
  • HOME
  • WHY US
  • ABOUT
  • SIGN IN
  • SIGN UP

Top Ad

hem-onc-updates

Advertisement

KEYTRUDA® (Pembrolizumab)

November 28, 2018April 5, 2020 RR FDA Approvals
Liver Cancer (Hepatocellular)

The FDA on November 9, 2018 granted accelerated approval to KEYTRUDA® for patients with Hepatocellular Carcinoma (HCC) who have been previously treated with Sorafenib. KEYTRUDA® is a product of Merck & Co. Inc.

Related Posts:

  • KEYTRUDA® (Pembrolizumab)
  • KEYTRUDA® (Pembrolizumab)
  • KEYTRUDA® (Pembrolizumab)
  • KEYTRUDA® (Pembrolizumab)
  • KEYTRUDA® (Pembrolizumab)
  • KEYTRUDA® (Pembrolizumab)

Post navigation

LORBRENA® (Lorlatinib)
ADCETRIS® (Brentuximab vedotin)

Bottom Ad

hem-onc-updates

Advertisement

Subscribe

Subscribe

Ad 1

OncoPrescribe-Ad

Advertisement

Ad 2

OncoPrescribe-CDC

Advertisement

Ad 3

OncoPrescribe-Ad

Advertisement

Ad 4

OncoPrescribe

Advertisement

  • PRIVACY
  • TERMS
  • DISCLAIMER
  • CONTACT
OncoPrescribe, LLC. All Rights Reserved